Full-Time
Updated on 8/11/2026
Supplemental health and life insurance provider
$123k - $170k/yr
Remote in USA + 2 more
More locations: Columbus, GA, USA | Columbia, SC, USA
Hybrid
Remote work is within the continental United States; remote employees may occasionally be asked to visit an office. Within 50 miles of Columbus, GA or Columbia, SC requires at least 60% in-office work.
Bachelor's, Master's
See people who can refer or advise you
Aflac provides supplemental health and life insurance products to individuals and families, operating mainly in two regions: Aflac Japan and Aflac U.S. Its policies are designed to cover out-of-pocket costs from health events and income loss, including cancer, critical illness, accidents, hospital stays, and life events. These benefits are paid directly to policyholders to help manage medical expenses not fully covered by primary insurance. The products are distributed through a network of independent agents, brokers, and financial advisors, enabling a high-volume, low-premium model that supports a large, stable customer base and ongoing revenue. Japan is its largest market, and the company uses this broad distribution and scale to differentiate itself from competitors. The goal is to provide straightforward financial protection against unexpected health-related costs while expanding its presence in the U.S. and Japanese markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
Columbus, Georgia
Founded
1955
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Hybrid Work Options
Remote Work Options
Aflac reported second-quarter revenue of $4.22 billion, meeting Wall Street expectations but declining 6.9% year on year. Adjusted earnings per share of $1.75 also met analyst estimates. The supplemental insurance provider attributed the revenue decline to tough comparisons in Japan following last year's cancer insurance product launch and shifting consumer preferences. However, CEO Daniel Amos highlighted solid growth from new offerings including Tsumitasu and Anshin Palette. In the US, group voluntary products and network dental and vision sales showed strength, with dental and vision product sales rising 47%. The company maintained expense discipline despite inflationary pressures. Looking ahead, Aflac plans to focus on product innovation in Japan, continued US group product momentum, and enhanced capital management. Management emphasised its commitment to dividend growth and share repurchases.
Aflac reported second-quarter revenue of $4.12 billion, missing analyst estimates of $4.23 billion and marking a 9.2% year-on-year decline. The supplemental insurance provider's adjusted earnings per share of $1.75 met expectations. The company's book value per share reached $60.35, beating estimates by 9.3% and showing 18.7% year-on-year growth. Pre-tax profit was $995 million, with a 24.2% margin. Chairman and CEO Daniel P. Amos highlighted solid earnings execution and new opportunities in Japan through products including Anshin Palette medical insurance and Miraito cancer insurance. In the US, Aflac is focusing on supplemental health products for employers. Over the past five years, Aflac's revenue has declined at a 5.1% annual rate, reflecting ongoing demand challenges.
Aflac Incorporated reported second quarter 2026 results with net earnings of $825 million, or $1.63 per diluted share, compared with $599 million, or $1.11 per diluted share a year ago. Total revenues decreased 1.0% to $4.1 billion. Adjusted earnings were $883 million, down 7.7% from $957 million in the prior year quarter. Adjusted earnings per diluted share decreased 1.7% to $1.75. The company returned $1.3 billion to shareholders through $983 million in share repurchases and $309 million in dividends. Chairman and CEO Daniel Amos highlighted successful product initiatives in Japan and focus on supplemental health products in the US. The board declared a third quarter dividend of $0.61 per share, payable on 1 September 2026 to shareholders of record on 19 August 2026.
Aflac has filed an omnibus shelf registration statement covering common stock, debt securities, warrants and other instruments, whilst launching its Fit Checks cancer screening awareness campaign with fashion designer Rachel Zoe. The campaign uses QR-enabled fashion pieces to link wearable design with cancer risk education. The moves demonstrate Aflac's strategy of combining capital markets flexibility with brand-building in preventive health. However, the initiatives don't materially change near-term earnings catalysts or key risks including declining Japanese premiums, currency volatility and investment income pressure. The company's second quarter 2026 earnings release, scheduled for 6-7 August, will provide insight into whether new products and digital initiatives are improving premium trends and margins in Japan and the US, Aflac's primary markets.
US insurer Aflac has sold a ¥65.9 billion ($415 million) yen bond across four tranches, with the 10-year tenor carrying a 3.482% coupon. The offering follows similar moves by foreign issuers including Alphabet and Berkshire Hathaway tapping Japan's credit market. The issuance marks a continuation of Aflac's regular yen bond programme, though the amount was below last year's ¥74.9 billion. Foreign borrowers are capitalising on relatively low funding costs in Japan, benefiting from the wide gap between US and Japanese interest rates. Yen bond issuance by overseas borrowers has surged more than 250% this year to approximately ¥1.6 trillion as of 20 May, compared to the same period in 2025, according to Bloomberg data.